Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Hong-Lee Yu who wrote (683)	6/30/1998 6:56:00 PM
From: Harold Engstrom	Read Replies (3) \| Respond to of 1686

Hong-Lee, today Berlex "announced that results from an interim analysis of a European study in secondary progressive multiple sclerosis (MS) are included in a Supplement to their Biologic License Application (BLA) filed today with the U.S. Food and Drug Administration (FDA)." The data is supposed by Berlex to be very strong. I read this as a big plus for Biogen, itself well into a study meant to bolster their own case for an expanded label into the secondary progressive indication. Biogen said it was ready for a relaunch in 2000, but perhaps Biogen's study will conclude early as well and we'll see a relaunch much sooner. Does anyone have an opinion about this development?